Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 84 of the 115 references it cites were found in a registry or an index.

Combination therapies for the optimisation of Bispecific T-cell Engagers in cancer treatment

Open access
Zhu, Winston M, Middleton, Mark R · 2023 · Immunotherapy Advances

Abstract

Summary: Bispecific T-cell engagers (BiTEs) redirect endogenous T-cell populations to cells expressing tumour-associated antigens to induce tumour cell killing. This inherently relies upon a cytotoxic T-cell population that is able to be recruited. In many cancers, immune checkpoints and other immunosuppressive factors in the tumour microenvironment lead to a population of anergic T-cells which cannot be redirected to tumour killing and thus impede the efficacy of BiTE therapy. Furthermore, there is evidence that BiTE therapy itself can increase immune checkpoint expression, and this is thought to be a major escape mechanism for the BiTE therapy blinatumomab. To overcome these inadequate T-cell responses, BiTEs may be combined with checkpoint inhibitors, chemotherapy, costimulatory molecules or oncolytic viruses. Study of these combinations is needed to expand the use of BiTEs in solid malignancies. This review covers the rationale, preclinical evidence and any clinical trials for these combination therapies and a few other less-studied combinations.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/immadv/ltad013

Cites

84 of 84 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. The cancer-immunity cycle (adapted from [1]). Tumour cell death leads to release of antigens which are taken up by antigen presenting cells (APCs). These travel to lymph nodes and activate lymphocytes, including cytotoxic T-lymphocytes (CTLs) which travel to the tumour site in the circulation and to the infiltrate by extravasation. These infiltrating CTLs cause tumour cell lysis which releases further tumour antigens that perpetuate the cycle. Produced using biorender.com.
Figure 1. The cancer-immunity cycle (adapted from [1]). Tumour cell death leads to release of antigens which are taken up by antigen presenting cells (APCs). These travel to lymph nodes and activate lymphocytes, including cytotoxic T-lymphocytes (CTLs) which travel to the tumour site in the circulation and to the infiltrate by extravasation. These infiltrating CTLs cause tumour cell lysis which releases further tumour antigens that perpetuate the cycle. Produced using biorender.com.CC BY · PubMed Central
Figure 2. Mechanism of BiTE-mediated tumour lysis. BiTEs form an immunological synapse between T-cells and TAA presenting cells by binding CD3 (most commonly, but other T-cell-associated targets such as CD28 or 4-1BB exist, as discussed below) and a TAA of choice. Binding of both arms of the BiTE activates the T-cell and leads to degranulation of cytotoxic perforins and granzyme B across the immunological synapse, leading to tumour cell lysis [2]. As the BiTE depicted directly targets CD3 on T-cells, activation occurs in a TCR-independent fashion that results in activation of a polyclonal population of T-cells. Crucially, BiTE-mediated tumour lysis would also perpetuate the cancer-immunity (depicted in Figure 1) because activated T-cells secrete immune activating cytokines, and tumour cell lysis leads to antigen release, uptake by APCs and subsequent immune activation (Figure 1; steps 4 and 1). Produced using biorender.com.
Figure 2. Mechanism of BiTE-mediated tumour lysis. BiTEs form an immunological synapse between T-cells and TAA presenting cells by binding CD3 (most commonly, but other T-cell-associated targets such as CD28 or 4-1BB exist, as discussed below) and a TAA of choice. Binding of both arms of the BiTE activates the T-cell and leads to degranulation of cytotoxic perforins and granzyme B across the immunological synapse, leading to tumour cell lysis [2]. As the BiTE depicted directly targets CD3 on T-cells, activation occurs in a TCR-independent fashion that results in activation of a polyclonal population of T-cells. Crucially, BiTE-mediated tumour lysis would also perpetuate the cancer-immunity (depicted in Figure 1) because activated T-cells secrete immune activating cytokines, and tumour cell lysis leads to antigen release, uptake by APCs and subsequent immune activation (Figure 1; steps 4 and 1). Produced using biorender.com.CC BY · PubMed Central
Figure 3. Combination therapies for BiTEs. A depiction of how BiTE combination strategies discussed. Single cell used to represent population of T cells and tumour cells for clarity. BiTE-induced tumour cell killing may be inhibited by immunosuppressive immune checkpoints, indicating that checkpoint inhibitors may synergise with BiTEs. Furthermore, pairing the traditional CD3xTAA BiTE with a CD28xTAA BiTE replicates costimulation (signal 2), leading to better T-cell activation directed towards tumour cells. Oncolytic viruses (OVs) has two distinct mechanisms. Firstly, viral oncolysis promotes inflammation (via the cancer-immunity cycle; Figure 1). Secondly, OVs can also be armed with BiTEs (OV-BiTEs), leading to selective delivery of a BiTE payload to tumour cells. OV-BiTEs may be targeted to tumour cells either by intratumoral injection (as depicted), or selective tropisms that limit replication exclusively to tumour cells. Produced using biorender.com.
Figure 3. Combination therapies for BiTEs. A depiction of how BiTE combination strategies discussed. Single cell used to represent population of T cells and tumour cells for clarity. BiTE-induced tumour cell killing may be inhibited by immunosuppressive immune checkpoints, indicating that checkpoint inhibitors may synergise with BiTEs. Furthermore, pairing the traditional CD3xTAA BiTE with a CD28xTAA BiTE replicates costimulation (signal 2), leading to better T-cell activation directed towards tumour cells. Oncolytic viruses (OVs) has two distinct mechanisms. Firstly, viral oncolysis promotes inflammation (via the cancer-immunity cycle; Figure 1). Secondly, OVs can also be armed with BiTEs (OV-BiTEs), leading to selective delivery of a BiTE payload to tumour cells. OV-BiTEs may be targeted to tumour cells either by intratumoral injection (as depicted), or selective tropisms that limit replication exclusively to tumour cells. Produced using biorender.com.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 115 references

Research works printed but not linked: 1

  1. Litzow, 2022, Consolidation therapy with blinatumomab improves overall survival in newly diagnosed adult patients with B-lineage acute lymphoblastic leukemia in measurable residual disease negative remission: results from the ECOG-ACRIN E1910 randomized phase III National Cooperative Clinical Trials Network trial, LBA-1

Cited by

See all 46

Metadata

Authors
Zhu, W. M., & Middleton, M. R.
Affiliations
University of Oxford (GB)
Corresponding author
Zhu, Winston M
Venue
Immunotherapy Advances
Published
2023-01-01
Volume
3
Issue
1
Pages
ltad013-ltad013
ISSN
2732-4303 (ISSN-L)
OpenAlex
W4385713649
Cited by
46
References
115
Citations by year
2026: 15 · 2025: 17 · 2024: 11 · 2023: 3
FWCI
1.49
Type
journal article
Language
en
Open access
Locations
  • Immunotherapy Advances (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • Roche
  • AstraZeneca
  • Novartis
  • Millenium
  • Immunocore
  • Eisai
  • Merck
  • Rigontec
  • BiolineRx
  • Array Biopharma
  • Pfizer
  • Kineta
  • Replimune
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
bispecific T-cell engagers, combination therapy, immune checkpoint, tumor microenvironment, T cell anergy, blinatumomab, immune checkpoint inhibitors, oncolytic viruses, costimulatory molecules, chemotherapy, solid tumors, cancer immunotherapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Combination therapies for the optimisation of Bispecific T-cell Engagers in cancer treatment. https://app.cochat.ai/papers/10.1093/immadv/ltad013
The paper
Zhu, W. M., & Middleton, M. R. (2023). Combination therapies for the optimisation of Bispecific T-cell Engagers in cancer treatment. Immunotherapy Advances. https://doi.org/10.1093/immadv/ltad013

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.